SavedAdd your journal

Journals / TSK Koruyucu Hekimlik Bülteni / 2013 / Cilt: 12 - Sayı: 3

[Overview of current humman papilloma virus (hpv) vaccination]

Human papilloma virüs (hpv) aşılamasına güncel bakış

CUMHUR ARTUK
Hanefi GÜL CEM
Ömer COŞKUN
Pages
327–334
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This topic will cover issues related to HPV infections, routine HPV immunization recommendations, vaccination in special patient populations, the cost-effectiveness of HPV vaccination, and vaccine safety.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Persistent viral infection with high-risk human papillomavirus (HPV) genotypes causes virtually all cancer of the cervix.
📊
Key Findings & Data:The same HPV genotypes (“types”) also cause cases of anal cancer.
💡
Conclusion & Impact:This topic will cover issues related to HPV infections, routine HPV immunization recommendations, vaccination in special patient populations, the cost-effectiveness of HPV vaccination, and vaccine safety.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Persistent viral infection with high-risk human papillomavirus (HPV) genotypes causes virtually all cancer of the cervix. The same HPV genotypes (“types”) also cause cases of anal cancer. Cervical cancer is the third most frequent cancer in women worldwide after breast and colorectal cancers. It ranks fourth of women’s cancers according to the mortality ratio. Two vaccines have been developed against HPV infection; one is a quadrivalent vaccine (GardasilTM) and the other is a bivalent vaccine (CervarixTM). This topic will cover issues related to HPV infections, routine HPV immunization recommendations, vaccination in special patient populations, the cost-effectiveness of HPV vaccination, and vaccine safety.

Özet

Yüksek riskli Human Papillomavirüs (HPV) tiplerinin neden olduğu uzun süreli viral enefeksiyonlar serviks kanserinin nedenidir. Aynı tipler anal kanserlerin de etkenidir. Serviks kanseri, tüm dünyada kadın kanserleri içerisinde meme ve kolorektal kanserlerden sonra üçüncü sıklıkta yer almaktadır. Mortalite oranlarına göre kadın kanserleri içinde dördüncü sırada yer almaktadır. İki tip HPV’ye karşı aşı geliştirilmiştir. Biri Kuadrivalan aşı (GardasilTM), diğeri Bivalan aşı (CervarixTM)’dır. Bu yazıda HPV enfeksiyonları, rutin HPV immünizasyonu önerileri, özel hasta popülâsyonlarında aşılama, aşının maliyet etkinliği ve aşı güvenliği ile ilgili konular ele alınacaktır.

🔖

Cite This Article

ARTUK, C., CEM, H. G., COŞKUN, Ö. (2013). [Overview of current humman papilloma virus (hpv) vaccination]. TSK Koruyucu Hekimlik Bülteni, Cilt: 12 - Sayı: 3, 327–334. https://ajindex.com/articles/128480

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893-2917
  2. American Cancer Society (ACS). Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010
  3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19
  4. Munoz N, Bosch FX, de Sanjosé et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med. 2003; 348(6): 518-27
  5. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005; 6: 204
  6. Woodman CBJ, Collins SI, Young LS. The nature history of cervical HPV infection: unresolved issues. Nat Rev Canad. 2007; 7: 11-22
  7. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis. 2001; 183: 1554–64
  8. Pakin DM, Bray F. Chapter 2: the burden of HPV related cancer. Vaccine 2006; 24 (Suppl 3): p.11- 25
  9. Vanchiere JA, Demmler GJ: Human Polyomaviruses and Papillomaviruses, “Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (eds): Textbook of Pediatric Infectious Diseases. 5th edition. Saunders, Philadelphia; 2004. p. 1809-31
  10. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. Can Med Assoc J. 2003; 168: 421-5
  11. Munoz N, Castellsague X, Gonzales AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006; 24: 1-10
  12. Dunne EF, Unger ER, Sternberg M, et al: Prevalence of HPV infection among females in the United States, JAMA. 2007; 297(8): 813-9
  13. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006; 24: 16-22
  14. Cervarix™--a second HPV vaccine. Med Lett Drugs Ther. 2010; 52(1338): 37-8
  15. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010; 10: 845
  16. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2010. Ann Intern Med. 2010; 152: 36
  17. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix™) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (